| Cash Flow | 2025-06-30 |
|---|---|
| Equity-based compensation | 60 |
| Non-cash lease expense | -81 |
| Net loss | -6,499 |
| Prepaid expenses and other current assets and other non-current assets | -9 |
| Other assets | -761 |
| Lease liability | -78 |
| Accrued expenses | -33 |
| Funds receivable from new jersey net operating loss | 0 |
| Accounts payable | 914 |
| Abandonment and expiration of patents and trademark rights | 615 |
| Loss on issuance of warrants | 0 |
| Loss (gain) on sale of marketable investments | 18 |
| Depreciation of property and equipment | 19 |
| Amortization of patent, trademark rights | 94 |
| Amortization of financial obligation | 183 |
| Net cash used in operating activities | -3,892 |
| Proceeds from sale of marketable investments | 2,026 |
| Purchase of marketable investments | 91 |
| (purchase) abandonment of patent and trademark rights | 283 |
| Net cash provided by investing activities | 1,652 |
| Proceeds from note payable, net of issuance costs | 250 |
| Proceeds from sale of stock, net of issuance costs | 765 |
| Proceeds from issuance of equity warrants | 0 |
| Net cash provided by financing activities | 1,015 |
| Net decrease in cash and cash equivalents | -1,225 |
AIM ImmunoTech Inc. (AIMI)
AIM ImmunoTech Inc. (AIMI)